A study of the clinical effects of clindamycin on respiratory infections -Focusing on inhibition of β-lactamase production-

Atsushi Saito; Nobuchika Kusano; Hiroshi Fukuhara; Rinzo Soejima; Chikara Nakahama; Yoshihito Niki; Koji Hashiguchi; Keizo Yamaguchi; Kazuhiro Tateda; Yoshikazu Ishii; Akira Ohno; Masumi Tomisawa; Akira Watanabe; Kazunao Niitsuma; Masaki Arakawa; Kouichi Wada; Mitsuru Hayase; Satoshi Iwata; Koichiro Nakata; Takashi Inamatsu; Izumi Hayashi; Harumi Shishido; Yasuo Matsuoka; Shigeki Odagiri; Shigeo Takizawa; Masahito Kato; Toshiyuki Yamamoto; Keiichi Mikasa; Masayoshi Sawaki; Nobuhiro Narita; Masao Kuwabara; Isao Nakamura; Yoshihiro Takizawa; Hozumi Yamada; Masaru Nasu; Keizo Matsumoto; Atushi Takahashi; Kohei Hara; Hironobu Koga; Shigeru Kohno

doi:10.11250/chemotherapy1953.41.1232

A study of the clinical effects of clindamycin on respiratory infections -Focusing on inhibition of β-lactamase production-

Atsushi Saito, Nobuchika Kusano, Hiroshi Fukuhara, Rinzo Soejima, Chikara Nakahama, Yoshihito Niki, Koji Hashiguchi, Keizo Yamaguchi, Kazuhiro Tateda, Yoshikazu Ishii, Akira Ohno, Masumi Tomisawa, Akira Watanabe, Kazunao Niitsuma, Masaki Arakawa, Kouichi Wada, Mitsuru Hayase, Satoshi Iwata, Koichiro Nakata, Takashi InamatsuIzumi Hayashi, Harumi Shishido, Yasuo Matsuoka, Shigeki Odagiri, Shigeo Takizawa, Masahito Kato, Toshiyuki Yamamoto, Keiichi Mikasa, Masayoshi Sawaki, Nobuhiro Narita, Masao Kuwabara, Isao Nakamura, Yoshihiro Takizawa, Hozumi Yamada, Masaru Nasu, Keizo Matsumoto, Atushi Takahashi, Kohei Hara, Hironobu Koga, Shigeru Kohno

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

The efficacy and safety of injectable clindamycin-2-phosphate (CLDM) and a β-lactam antibiotic in combination were assessed at 25 institutions in Japan, focusing especially on CLDM's inhibitory effect on the production of β-lactamase. A total of 31 cases were included in the study. There were 4 cases the responded well to the β-lactam antibiotic alone and the one case also treated with a steroid. The other 26 cases consisted of 10 cases of chronic bronchitis, 8 of bronchiectasis, 1 of diffuse panbronchiolitis, 6 of pneumonia, and 1 of lung abscess. The medication was started with intravenous drip infusion of a recommended dose of β-lactam antibiotic divided in two doses, and when the drug did not show efficacy by treatment day 3, 1, 200-2, 400 mg/day of CLDM in two equal doses was added starting on day 4. CLDM was given generally up to day 7, but up to day 10 in some cases, to assess the efficacy of combination therapy. Final clinical efficacy was good in 90.0% (9/ 10) of the cases of chronic bronchitis, 71.4% (5/7) of the cases of bronchiectasis, 100% (1/1) of the cases of diffuse panbronchiolitis, and 100% (5/5) of the cases of pneumonia, but poor in the single case of lung abscess. Sputum β-lactamase activity had decreased by day 4 of combination therapy in all cases which had shown low or moderate (<500 μU/ml) β-lactamase activity before the addition of CLDM. In 8 of the 9 patients with high β-lactamase activity (>500 μU/ml), it started to tend to decline on day 1 of combination therapy. Clinical efficacy and β-lactamase activity were correlated: r=0.665 (p<0.01) in the high β-lactamase activity group and r=0.666 (p<0.01) in the low/moderate activity group. Side effects wer noted in 2 of the 31 cases, but both were mild and allowed continued treatment. A slight rise in S-GOT was detected in one case, but it returned to normal after the completion of therapy. These findings suggest the clinical usefulness of combination therapy with CLDM and a β-lactam antibiotic, partly due to CLDM's inhibitory effect on the production of β-lactamase.

Original language	English
Pages (from-to)	1232-1245
Number of pages	14
Journal	CHEMOTHERAPY
Volume	41
Issue number	11
DOIs	https://doi.org/10.11250/chemotherapy1953.41.1232
Publication status	Published - 1993
Externally published	Yes

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.41.1232

Cite this

Saito, A., Kusano, N., Fukuhara, H., Soejima, R., Nakahama, C., Niki, Y., Hashiguchi, K., Yamaguchi, K., Tateda, K., Ishii, Y., Ohno, A., Tomisawa, M., Watanabe, A., Niitsuma, K., Arakawa, M., Wada, K., Hayase, M., Iwata, S., Nakata, K., ... Kohno, S. (1993). A study of the clinical effects of clindamycin on respiratory infections -Focusing on inhibition of β-lactamase production-. CHEMOTHERAPY, 41(11), 1232-1245. https://doi.org/10.11250/chemotherapy1953.41.1232

Saito, A, Kusano, N, Fukuhara, H, Soejima, R, Nakahama, C, Niki, Y, Hashiguchi, K, Yamaguchi, K, Tateda, K, Ishii, Y, Ohno, A, Tomisawa, M, Watanabe, A, Niitsuma, K, Arakawa, M, Wada, K, Hayase, M, Iwata, S, Nakata, K, Inamatsu, T, Hayashi, I, Shishido, H, Matsuoka, Y, Odagiri, S, Takizawa, S, Kato, M, Yamamoto, T, Mikasa, K, Sawaki, M, Narita, N, Kuwabara, M, Nakamura, I, Takizawa, Y, Yamada, H, Nasu, M, Matsumoto, K, Takahashi, A, Hara, K, Koga, H & Kohno, S 1993, 'A study of the clinical effects of clindamycin on respiratory infections -Focusing on inhibition of β-lactamase production-', CHEMOTHERAPY, vol. 41, no. 11, pp. 1232-1245. https://doi.org/10.11250/chemotherapy1953.41.1232

@article{40d8273779e14fdf840f115603e62258,

title = "A study of the clinical effects of clindamycin on respiratory infections -Focusing on inhibition of β-lactamase production-",

abstract = "The efficacy and safety of injectable clindamycin-2-phosphate (CLDM) and a β-lactam antibiotic in combination were assessed at 25 institutions in Japan, focusing especially on CLDM's inhibitory effect on the production of β-lactamase. A total of 31 cases were included in the study. There were 4 cases the responded well to the β-lactam antibiotic alone and the one case also treated with a steroid. The other 26 cases consisted of 10 cases of chronic bronchitis, 8 of bronchiectasis, 1 of diffuse panbronchiolitis, 6 of pneumonia, and 1 of lung abscess. The medication was started with intravenous drip infusion of a recommended dose of β-lactam antibiotic divided in two doses, and when the drug did not show efficacy by treatment day 3, 1, 200-2, 400 mg/day of CLDM in two equal doses was added starting on day 4. CLDM was given generally up to day 7, but up to day 10 in some cases, to assess the efficacy of combination therapy. Final clinical efficacy was good in 90.0% (9/ 10) of the cases of chronic bronchitis, 71.4% (5/7) of the cases of bronchiectasis, 100% (1/1) of the cases of diffuse panbronchiolitis, and 100% (5/5) of the cases of pneumonia, but poor in the single case of lung abscess. Sputum β-lactamase activity had decreased by day 4 of combination therapy in all cases which had shown low or moderate (<500 μU/ml) β-lactamase activity before the addition of CLDM. In 8 of the 9 patients with high β-lactamase activity (>500 μU/ml), it started to tend to decline on day 1 of combination therapy. Clinical efficacy and β-lactamase activity were correlated: r=0.665 (p<0.01) in the high β-lactamase activity group and r=0.666 (p<0.01) in the low/moderate activity group. Side effects wer noted in 2 of the 31 cases, but both were mild and allowed continued treatment. A slight rise in S-GOT was detected in one case, but it returned to normal after the completion of therapy. These findings suggest the clinical usefulness of combination therapy with CLDM and a β-lactam antibiotic, partly due to CLDM's inhibitory effect on the production of β-lactamase.",

author = "Atsushi Saito and Nobuchika Kusano and Hiroshi Fukuhara and Rinzo Soejima and Chikara Nakahama and Yoshihito Niki and Koji Hashiguchi and Keizo Yamaguchi and Kazuhiro Tateda and Yoshikazu Ishii and Akira Ohno and Masumi Tomisawa and Akira Watanabe and Kazunao Niitsuma and Masaki Arakawa and Kouichi Wada and Mitsuru Hayase and Satoshi Iwata and Koichiro Nakata and Takashi Inamatsu and Izumi Hayashi and Harumi Shishido and Yasuo Matsuoka and Shigeki Odagiri and Shigeo Takizawa and Masahito Kato and Toshiyuki Yamamoto and Keiichi Mikasa and Masayoshi Sawaki and Nobuhiro Narita and Masao Kuwabara and Isao Nakamura and Yoshihiro Takizawa and Hozumi Yamada and Masaru Nasu and Keizo Matsumoto and Atushi Takahashi and Kohei Hara and Hironobu Koga and Shigeru Kohno",

year = "1993",

doi = "10.11250/chemotherapy1953.41.1232",

language = "English",

volume = "41",

pages = "1232--1245",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "11",

}

TY - JOUR

T1 - A study of the clinical effects of clindamycin on respiratory infections -Focusing on inhibition of β-lactamase production-

AU - Saito, Atsushi

AU - Kusano, Nobuchika

AU - Fukuhara, Hiroshi

AU - Soejima, Rinzo

AU - Nakahama, Chikara

AU - Niki, Yoshihito

AU - Hashiguchi, Koji

AU - Yamaguchi, Keizo

AU - Tateda, Kazuhiro

AU - Ishii, Yoshikazu

AU - Ohno, Akira

AU - Tomisawa, Masumi

AU - Watanabe, Akira

AU - Niitsuma, Kazunao

AU - Arakawa, Masaki

AU - Wada, Kouichi

AU - Hayase, Mitsuru

AU - Iwata, Satoshi

AU - Nakata, Koichiro

AU - Inamatsu, Takashi

AU - Hayashi, Izumi

AU - Shishido, Harumi

AU - Matsuoka, Yasuo

AU - Odagiri, Shigeki

AU - Takizawa, Shigeo

AU - Kato, Masahito

AU - Yamamoto, Toshiyuki

AU - Mikasa, Keiichi

AU - Sawaki, Masayoshi

AU - Narita, Nobuhiro

AU - Kuwabara, Masao

AU - Nakamura, Isao

AU - Takizawa, Yoshihiro

AU - Yamada, Hozumi

AU - Nasu, Masaru

AU - Matsumoto, Keizo

AU - Takahashi, Atushi

AU - Hara, Kohei

AU - Koga, Hironobu

AU - Kohno, Shigeru

PY - 1993

Y1 - 1993

N2 - The efficacy and safety of injectable clindamycin-2-phosphate (CLDM) and a β-lactam antibiotic in combination were assessed at 25 institutions in Japan, focusing especially on CLDM's inhibitory effect on the production of β-lactamase. A total of 31 cases were included in the study. There were 4 cases the responded well to the β-lactam antibiotic alone and the one case also treated with a steroid. The other 26 cases consisted of 10 cases of chronic bronchitis, 8 of bronchiectasis, 1 of diffuse panbronchiolitis, 6 of pneumonia, and 1 of lung abscess. The medication was started with intravenous drip infusion of a recommended dose of β-lactam antibiotic divided in two doses, and when the drug did not show efficacy by treatment day 3, 1, 200-2, 400 mg/day of CLDM in two equal doses was added starting on day 4. CLDM was given generally up to day 7, but up to day 10 in some cases, to assess the efficacy of combination therapy. Final clinical efficacy was good in 90.0% (9/ 10) of the cases of chronic bronchitis, 71.4% (5/7) of the cases of bronchiectasis, 100% (1/1) of the cases of diffuse panbronchiolitis, and 100% (5/5) of the cases of pneumonia, but poor in the single case of lung abscess. Sputum β-lactamase activity had decreased by day 4 of combination therapy in all cases which had shown low or moderate (<500 μU/ml) β-lactamase activity before the addition of CLDM. In 8 of the 9 patients with high β-lactamase activity (>500 μU/ml), it started to tend to decline on day 1 of combination therapy. Clinical efficacy and β-lactamase activity were correlated: r=0.665 (p<0.01) in the high β-lactamase activity group and r=0.666 (p<0.01) in the low/moderate activity group. Side effects wer noted in 2 of the 31 cases, but both were mild and allowed continued treatment. A slight rise in S-GOT was detected in one case, but it returned to normal after the completion of therapy. These findings suggest the clinical usefulness of combination therapy with CLDM and a β-lactam antibiotic, partly due to CLDM's inhibitory effect on the production of β-lactamase.

AB - The efficacy and safety of injectable clindamycin-2-phosphate (CLDM) and a β-lactam antibiotic in combination were assessed at 25 institutions in Japan, focusing especially on CLDM's inhibitory effect on the production of β-lactamase. A total of 31 cases were included in the study. There were 4 cases the responded well to the β-lactam antibiotic alone and the one case also treated with a steroid. The other 26 cases consisted of 10 cases of chronic bronchitis, 8 of bronchiectasis, 1 of diffuse panbronchiolitis, 6 of pneumonia, and 1 of lung abscess. The medication was started with intravenous drip infusion of a recommended dose of β-lactam antibiotic divided in two doses, and when the drug did not show efficacy by treatment day 3, 1, 200-2, 400 mg/day of CLDM in two equal doses was added starting on day 4. CLDM was given generally up to day 7, but up to day 10 in some cases, to assess the efficacy of combination therapy. Final clinical efficacy was good in 90.0% (9/ 10) of the cases of chronic bronchitis, 71.4% (5/7) of the cases of bronchiectasis, 100% (1/1) of the cases of diffuse panbronchiolitis, and 100% (5/5) of the cases of pneumonia, but poor in the single case of lung abscess. Sputum β-lactamase activity had decreased by day 4 of combination therapy in all cases which had shown low or moderate (<500 μU/ml) β-lactamase activity before the addition of CLDM. In 8 of the 9 patients with high β-lactamase activity (>500 μU/ml), it started to tend to decline on day 1 of combination therapy. Clinical efficacy and β-lactamase activity were correlated: r=0.665 (p<0.01) in the high β-lactamase activity group and r=0.666 (p<0.01) in the low/moderate activity group. Side effects wer noted in 2 of the 31 cases, but both were mild and allowed continued treatment. A slight rise in S-GOT was detected in one case, but it returned to normal after the completion of therapy. These findings suggest the clinical usefulness of combination therapy with CLDM and a β-lactam antibiotic, partly due to CLDM's inhibitory effect on the production of β-lactamase.

UR - http://www.scopus.com/inward/record.url?scp=0027763390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027763390&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.41.1232

DO - 10.11250/chemotherapy1953.41.1232

M3 - Article

AN - SCOPUS:0027763390

SN - 0009-3165

VL - 41

SP - 1232

EP - 1245

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

IS - 11

ER -

A study of the clinical effects of clindamycin on respiratory infections -Focusing on inhibition of β-lactamase production-

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this